** This website does not use cookies **

NTAG logo

NHS logo




tablets



Recommendations and Appraisals

Central nervous system

On this page you will find our appraisal documents and recommendations sorted by BNF chapter.

Where a decision is >24 months old; these are highlighted in red. If you are a clinician working within the
NTAG region and would like to prioritise an old decision for re-review please contact the professional secretary
on rdtc.rxsupp@nuth.nhs.uk


 

spacer 

Title

Documents

Decision

Date

 

 

 

spacer 

spacer 

 

spacer 

spacer 

 

Agomelatine (Valdoxan®) for depression (NETAG)

Recommendation

Appraisal

Recommended for the treatment
of depression only following an adequate trial of at least three alternative antidepressant drugs at maximally tolerated doses
 

13/07/2010

 

  

Aripiprazole long acting injection (Abilify Maintena®) for schizophrenia
 

Recommendation

North of England Guidance
 

Appraisal

Recommended as per the North
of England Guidance

09/04/2015

 

 New
20 Nov 2018

Erenumab and galcanezumab for prophylaxis of migraine
 

Recommendation

Appraisal

Not recommended
 

20/11/2018

 

 

e-Voke® electronic cigarette for smoking cessation
 

Recommendation

Appraisal

Not recommended

05/04/2016

 

 

 Liraglutide (Saxenda®) for Obesity in adults

Recommendation

 

 

Not recommended

 

05/09/2017

 

   

Lurasidone (Latuda®) for the treatment of schizophrenia in adults
 

Recommendation

Appraisal

Not recommended

09/04/2015

 

 updated
04 Sep 2018

Lycra Garments for the management of cerebral palsy and other neurological or musculoskeletal conditions
 

Recommendation

Appraisal

Not recommended

04/09/2018

 

 

Nalmefene in the management of alcohol dependence
 

Recommendation

 

Appraisal

NTAG recommendation
superseded NICE TA now
available

 

25/02/2014

 

 

Novel fentanyl products (Abstral®, Effentora® Instanyl® and PecFent®): Updated appraisal for breakthrough pain associated with cancer (NETAG)
 

Recommendation

Appraisal

Not recommended

12/07/2011

 

 

Paliperidone long-acting monthly(Xepilon®)  and three monthly (Trevicta®) injection for schizophrenia
 

Recommendation

North of England Guidance
 

Appraisal

Recommended as per the North
of England Guidance

05/09/2017

 

 

Perampanel (Fycompa®) for Partial-onset (focal) epilepsy (NETAG)

Recommendation

Appraisal

Recommended only when other treatment options recommended by NICE have been tried or fully considered
 

13/11/2012

 

 updated
05 Nov 2018

Pitolisant (Wakix®) for the treatment of narcolepsy with or without cataplexy in adults

Recommendation

Appraisal

Recommended as per the regionally agreed guidance

05/11/2018

 

 

 

Appeal Appraisal
 

 

 

 

 

 

Pitolisant (Wakix®) Treatment Pathway
 

 

 

 

 

Qutenza® (capsaicin patch) for neuropathic pain (updated)

Recommendation

Appraisal

Recommended as a fourth line agent in line with treatment pathway

06/06/2017

 

 

 

Qutenza® Treatment
Pathway

 

 

 

 

 

Sativex® for the treatment of non-MS pain
 

Recommendation

Appraisal

Not recommended

25/11/2014

 

 

Sodium oxybate(Xyrem®) for Narcolepsy with Cataplexy in adult patients (updated)
 

Recommendation

Appraisal

Recommended for continuation of treatment only, if benefited as a child.
 

06/06/2017

 

 updated
04 Sep 2018

Transcutaneous vagus nerve stimulation for treatment of cluster headache and migraine
 

Recommendation

Appraisal

Not recommended

04/09/2018

 

 

 

 

 

 

 

 

NTAG image of tablets

spacer

       Terms and Conditions              RSS Feed              Archived Recommendations

spacer